Penumbra (PEN) Preferred Stock Liabilities (2014)

Penumbra's (PEN) quarterly Preferred Stock Liabilities came in at $111.5 million in Q4 2014.

Penumbra (PEN) Preferred Stock Liabilities (2014) Analysis & Trends

Penumbra (PEN) has 1 years of Preferred Stock Liabilities data on file, last reported at $111.5 million in Q4 2014.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $111.5 million in Q4 2014; TTM through Dec 2014 was $111.5 million, a N/A change from a year earlier, with the FY2014 full-year figure at $111.5 million, up 98.26% from the prior year.
Preferred Stock Liabilities for Q4 2014 stood at $111.5 million.
Over the last five years, Preferred Stock Liabilities for PEN reached as high as $111.5 million in Q4 2014 and fell as low as $111.5 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Penumbra	12.48 Bn	11.87 Bn	253.41 Mn	-

Download Data

Date	Value
Dec 31, 2014	111.47 Mn